Global biotechnology and pharmaceutical companies that seek to capitalize on Asia's growth story are locating first-in-Asia manufacturing facilities and headquarters offices in Singapore. Fixed asset investments from biomedical companies exceeded $800 million in 2009, according to the Island state government's planning agency, the Economic Development Board.
"Asia's growth presents tremendous opportunities but its diversity also poses challenges. In global companies' foray into Asia, Singapore can help to enhance manufacturing and business excellence to strengthen their foothold in Asia," said Beh Kian Teik, director, biomedical sciences, at Singapore's EDB.
Core site of manufacturing excellence in Asia
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze